Reports Q3 revenue $7.34M, consensus $6.33M. “With strong quarter over quarter growth and robust payer coverage one year into the launch of ZTALMY, we continue to demonstrate our unique commercial capabilities in the orphan epilepsy space and are enthused by the opportunity ZTALMY and the ganaxolone franchise represent as an important long-term value driver for Marinus,” said Scott Braunstein, Chairman and Chief Executive Officer of Marinus.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRNS:
- MRNS Earnings this Week: How Will it Perform?
- Biotech Alert: Searches spiking for these stocks today
- Marinus Pharmaceuticals price target raised to $15 from $13 at Ladenburg
- 3 Best Stocks to Buy Now, 9/20/2023, According to Top Analysts
- Marinus Pharmaceuticals price target raised to $21 from $20 at RBC Capital
